Risk stratification of sudden cardiac death in hypertrophic cardiomyopathy

Nature Clinical Practice Cardiovascular Medicine

Volumn 4, Issue 12, 2007, Pages 667-676

  Miller, Marc A ^a   Gomes, J Anthony ^a   Fuster, Valentin ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ANAMNESIS; BLOOD PRESSURE; DEFIBRILLATOR; EXERCISE; FAMILY HISTORY; GENE MUTATION; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SUDDEN DEATH; SYNCOPE; T WAVE;

ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; HEART CONDUCTION SYSTEM; HUMANS; MAGNETIC RESONANCE IMAGING; RISK ASSESSMENT; RISK FACTORS;

EID: 36448934480     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1057     Document Type: Review

References (70)

1. Elliott PM et al. (2006) Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 92 785-791
2. Maron BJ et al. (2000) Epidemiology of hypertrophic cardiomyopathy-related death: Revisited in a large non-referral-based patient population. Circulation 102:858-864
3. Maron BJ et al. (2003) American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J AM Coll Cardiol 42:1687-1713
4. Maron BJ et al. (2003) Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation 107:2872-2875
5. Maron BJ et al. (2000) Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 342 365-373
6. Elliott PM et al. (1999) Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 33: 1596-1601
7. Gehi AK et al. (2006) Evaluation and management of patients after implantable cardioverter-defibrillator shock. JAMA 296 2839-2847
8. Elliott PM et al. (2000) Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients. J Am Coll Cardiol 36:2212-2218
9. Maron EW et al. (11995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 92:785-789
10. Spirito P et al. (2000) Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342: 1778-1785
11. Elliott PM et al. (2001) Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 357: 420-424
12. Olivotto I et al. (2003) Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 41: 315-321
13. Maron BJ et al. (2003) Relation of extreme left ventricular hypertrophy to age in hypertrophic cardiomyopathy. Am J Cardiol 91: 626-628.
14. Sorajja P et al. (2006) Use of echocardiography in patients with hypertrophic cardiomyopathy: Clinical implications of massive hypertrophy. J Am Soc Echocardiogr 19: 788-795
15. Yoshida N at al. (1998) Exercise-induced abnormal blood pressure responses are related to subendocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol 32:1938-1942
16. Counihan PJ et al. (11991) Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation 84: 686-696
17. Ciampi Q et al. (2002) Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy. J Am Coll Cardiol 40 278-284
18. Sadoul N et al. (1997) Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 96: 2987-2991
19. Olivotto I et al. (1999) Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 33: 2044-2051
20. Behr ER et al. (2002) Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy. Card Electrophysiol Rev 6: 482-486
21. Lim PO et al. (2002) Vascular mechanisms of sudden death in hypertrophic cardiomyopathy, including blood pressure responses to exercise. Cardiol Rev 10: 15-23
22. Zipes DD et al. (2006) ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 48 e247-346
23. Katritsis DG et al. (2004) Nonsustained ventricular tachycardia: where do we stand? Eur Heart J 25: 1093-1099
24. Maron BJ et al. (1981) Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patents with hypertrophic cardiomyopathy: A prospective study. Am J Cardiol 48: 252-257
25. Spirito P et al. (1994) Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 90: 2743-2747
26. Monserrat L et al. (2003) Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients. J Am Coll Cardiol 42: 873-879
27. Adabag AS et al. (2006) Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol 45: 697-704
28. Kowey PR et al. (1984) Sustained arrhythmias in hypertrophic obstructive cardiomyopathy. N Engl J Med 310: 1566-1569
29. Fananapazir L et al. (1989) Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation 80: 1259-1268
30. Sneddon JF et al. (1994) Assessment ofthe diagnostic value of head-up tift testing in the evaluation of syncope in hypertrophic cardiomyopathy. Am J Cardiol 73: 601-604
31. Kofflard MJ et al. (2003) Hypertrophic cardiomyopathy in a large community-based population: Clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol 41: 987-993
32. Hunt SC et al. (1986) A comparison of positive family history definitions for defining risk of future disease. J Chronic Dis 39: 809-821
33. Maki S et al. (1998) Predictors of sudden cardiac death in hypertrophic cardlomyopathy. Am J Cardiol 82: 774-778
34. Maron BJ et al. (1999) Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 281: 650-655
35. Moolman JC et al. (1997) Sudden death due to troponin T mutations. J Am Coll Cardiol 29: 549-555
36. Maron BJ et al. (2002) Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 39: 301-307
37. Cha YM et al. (2007) Electrophysiologic manifestations of ventricular tachyarrhythmias provoking appropriate defibrillator interventions in high-risk patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 18: 301-307
38. Olivotto I et al. (2001) Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 104 2517-2524
39. Savelieva I et al. (2000) Clinical relevance of silent atrial fibrillation: Prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 4: 369-382
40. Maron MS et al. (2006) Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 114: 2232-2239
41. Maron MS et al. (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348: 295-303
42. Maron BJ et al. (2006) The dilemma of left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy: Do patients with gradients really deserve prophylactic defibrillators? Eur Heart J 27: 1895-1897.
43. Elliott PM et al. (2006) Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 27: 1933-19411
44. Cecchi F (2007) Does LV outflow tract obstruction increase the risk of sudden death in hypertrophic cardiomyopathy? Nat Clin Pract Cardiovasc Med 4: 194-195
45. Elliott P et al. (2006) Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy. Eur Heart J 27 3073
46. Seidman JG et al. (2001) The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 104 557-567
47. Jarcho JA et al. (1989) Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med 321: 1372-1378
48. Van Driest SL et al. (2002) Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic Gardiomyopathy. Circulation 106: 3085-3090
49. Van Driest SL et al. (2005) Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clin Proc 80: 463-469
50. Watkins H et al. (1995) Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 332: 1058-1064
51. Yamada M et al. (1998) Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome. Eur Heart J 19: 500-507
52. Sorajja P et al. (2006) Prognostic utility of single-photon emission computed tomography in adult-patients with hypertrophic cardiomyopathy. Am Heart J 151: 426-435
53. Basso C et al. (2000) Hypertrophic cardiomyopathy and sudden death in the young: Pathologic evidence of myocardial ischemia. Hum Pathol 31: 988-998
54. Choudhury L et al. (1997) Coronary vasodilator reserve in primary and secondary left ventricular, hypertrophy. A study with positron emission tomography. Eur Heart J 18: 108-116
55. Cecchi F et al. (2003) Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 349: 1027-1035
56. Yetman AT et al. (1998) Myocardial bridging in children with hypertrophic cardiomyopathy - a risk factor for sudden death. N Engl J Med 339: 1201-1209
57. Petersen SE et al. (2007) Evidence for microvasoular dysfunction in hypertrophic cardiomyopathy: New insights from multiparametric magnetic resonance imaging. Circulation 115: 2418-2425
58. Maron BJ et al. (2006) The head of trained Athletes: Cardiac remodeling and the risks of sports, including sudden death. Circulation 114: 1633-1644
59. Nagueh SF et al. (2006) Noninvasive cardiac imaging in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 48: 2410-2422
60. Gehi AK et al. (2005) Microvolt T-wave alternans for the risk stratification of ventricular tachyarrhythmic events: A meta-anatysis. J Am Coll Cardiol 46: 75-82
61. Momiyama Y et al. (1997) Exercise-induced T-wave alternans as a marker of high risk in patients with hypertrophic cardiomyopathy. Jpn Circ J 61: 650-656
62. Kuroda N et al. (2002) Clinical significance of T-wave alternans in hypertrophic cardiomyopathy. Circ J 66: 457-462
63. Wu E et al. (2001) Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 357: 21-28
64. Moon JC et al. (2004) The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43:2260-2264
65. Choudhury L et al. (2002) Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40: 2156-2164
66. Moon JC et al. (2003) Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 41: 1561-1567
67. McKenna WJ et al. (2002) Hypertrophic cardiomyopathy: Management, risk stratification, and prevention of sudden death; Heart 87 169-176
68. Begley DA et al. (2003) Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophip cardiomyopathy. Pacing Clin Electrophysiol 26: 1887-1896
69. Sears SF et al. (2000) Assessing the psychosocial impact of the ICD: A national survey at implantable cardioverter defibrillator health care providers. Pacing Clin Electrophysiol 23: 939-945
70. Maron BJ et al. (2007) Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 298: 405-412